Not investment advice. Educational platform. See Disclaimer.
NYSE: LH
Labcorp Holdings Inc.
Healthcare | Medical - Diagnostics & Research
$254.91-8.89 (-3.37%)as of 2026-07-14 20:08 UTC
Market Cap$20.9B
EPS (TTM)$10.46
Labcorp Holdings Inc. (NYSE: LH) is a $20.9B medical - diagnostics & research company trading at $254.91 (−3.4% today) — 24.4× trailing earnings, yielding 1.13%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 20:08 UTC.
52-Week Range
Low $252.38High $279.54
What Labcorp Holdings Inc. does
Labcorp provides laboratory testing and drug development services to doctors, hospitals, pharmaceutical companies, researchers, and patients across approximately 100 countries. The company operates through two main business segments: diagnostics (Dx) and drug development laboratory services (BLS), supported by nearly 71,000 employees. The company performs clinical laboratory tests and supports drug development, including providing support for newly approved FDA drugs and therapeutic products.
Summarized from Labcorp Holdings Inc.’s SEC filings · Read the filing ↗
Labcorp provides laboratory testing and drug development services to doctors, hospitals, pharmaceutical companies, researchers, and patients across approximately 100 countries.
What is LH's valuation?
LH trades at $254.91, 24.37× trailing earnings, 12.30× EV/EBITDA, as of 2026-07-14. It carries a 1.13% dividend yield.
When did LH last file with the SEC?
Labcorp Holdings Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-10. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 20:08 UTC. This page is also available as JSON at /api/data?ticker=LH and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for LH and 3,500+ tickers.